NYSE:SNY

Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Dynavax Technologies Corporation (NASDAQ: DVAX) is the standout mover heading into the Christmas break after Sanofi agreed to acquire the vaccine maker in an all-cash deal valued at about $2.2 billion. The transaction price — $15.50 per share in cash

24 December 2025

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies Corporation (NASDAQ: DVAX) is the center of the biotech tape on Wednesday, December 24, 2025, after Sanofi announced a deal to acquire the vaccine maker in an all-cash transaction valued at roughly $2.2 billion. The headline number investors

24 December 2025

Biotech Industry · Financial Forecasts · Investment Analysis · Mergers and Acquisitions · NASDAQ:DVAX · NYSE:SNY · Stock Market News

EU Stock Markets Today (24 December 2025): STOXX 600 Flat on Christmas Eve as BP Castrol Deal, Sanofi’s Dynavax Move and Record Metals Set the Tone

EU stock markets traded in a distinctly “holiday mode” on Wednesday, December 24, 2025, with liquidity thinning sharply as several exchanges either closed entirely or ran shortened sessions for Christmas Eve. The STOXX 600—a widely followed pan-European benchmark that investors often use as a proxy for

24 December 2025

Corporate Deals · European Economy · Financial News · Holiday Trading · NASDAQ:DVAX · NYSE:BP · NYSE:SNY · Stock Market Updates

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

As of Sunday, December 21, 2025, AbbVie Inc. (NYSE: ABBV) heads into a holiday-shortened trading week with shares hovering near the mid-$220s, after a high-volume rebound into Friday’s close. The setup for the week ahead is defined by two competing

21 December 2025

Drug Pricing · Financial News · Investment Analysis · NASDAQ:AMGN · NASDAQ:GILD · NYSE:ABBV · NYSE:BMY · NYSE:GSK · NYSE:MRK · NYSE:NVS · NYSE:SNY · Pharmaceuticals · Stock Market

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered

21 December 2025

Drug Pricing · FDA Updates · Mergers & Acquisitions · NASDAQ:AMGN · NASDAQ:GILD · NYSE:BMY · NYSE:GSK · NYSE:MRK · NYSE:NVS · NYSE:SNY · Pharma Stocks · Weekly Outlook

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements,

20 December 2025

Biotech · Drug Pricing · Healthcare · Market Outlook · NASDAQ:AMGN · NASDAQ:GILD · NYSE:BMY · NYSE:GSK · NYSE:MRK · NYSE:NVS · NYSE:SNY · Stock Market

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi stock is under pressure on December 15, 2025, after the French drugmaker disclosed two setbacks tied to its experimental multiple sclerosis (MS) medicine tolebrutinib—a regulatory delay in the U.S. for one progressive MS form and a failed Phase 3

15 December 2025

Analyst Forecasts · FDA News · NYSE:SNY · Pharmaceuticals · Sanofi · Stock Market

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Richmond’s New Pharma Giant: Overview of Lilly’s $5B Factory Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct

16 September 2025

Drug Industry · Eli Lilly · Innovation · Manufacturing · NASDAQ:AZN · NYSE:JNJ · NYSE:LLY · NYSE:NVS · NYSE:SNY · Pharmaceuticals

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Key Facts Scientific Breakthroughs & New Research Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests

30 August 2025

Biotech · Global News · Health · Medicine · NASDAQ:CYTK · NYSE:GSK · NYSE:SNY · Public Health

NYSE:SNY News 30 August 2025 - 24 December 2025